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Abstract 
Introduction: Experimental animal studies provided evidence for a synergistic effect of 
immunological and psychological stressors on subsequent sickness behaviors. Up to now, little 
corroborating evidence for such synergy exists for humans, in whom it may provide a 
mechanism leading to the expression of functional somatic symptoms. The aim of the present 
study was to determine an interaction between stress(-vulnerability) and an immunological 
activation on experimental pain sensitivity, i.e., pressure pain threshold and tolerance in healthy 
humans.  
Methods: In healthy female participants (n=25, mean age 22.3 years), negative affectivity (NA) 
and experienced stress were assessed by questionnaire before receiving a Salmonella typhi 
vaccine or saline control in a randomized blinded cross-over design. Pressure pain threshold was 
assessed at the lower back and calves and pain tolerance was assessed at the thumbnail, before 
and six hours after each injection. 
Results: Vaccination induced leukocytosis (+100%) and increased serum IL-6 (+670%). NA 
predicted decreased pain tolerance after vaccination (β=-.57, p=.007), but not after placebo 
(β=.25, p=.26). Post-hoc analyses also demonstrated an association with administration order. 
Discussion: NA moderated the effects of inflammation on pain tolerance. This finding is 
consistent with a synergistic model whereby inflammation may lower the threshold for pain 
reporting in individuals with increased vulnerability for somatic symptom reporting.  
 
Keywords: inflammation; inflammatory response; interleukin-6; cytokines; pain sensitivity;  
algometry; pain tolerance; pain threshold; pressure pain; experimental pain; vaccine; placebo; 
randomized control; stress; life events; negative affectivity; negative affect; human; 
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1. Introduction 
In reaction to an immunological challenge, immune-to-brain communication leads to a 
constellation of reversible behavioral and affective changes, denoted as sickness behavior (Hart, 
1988; Kent et al., 1992). These include lethargy, social withdrawal, and enhanced sensitivity to 
pain (Larson and Dunn, 2001; Yirmiya et al., 1994). Animal studies have demonstrated that 
(psychological) stress factors may sensitize this immune-to-brain communication, resulting in a 
prolonged or more severe expression of sickness behavior symptoms when an immunological 
stressor is applied (Anisman et al., 2007; Gibb et al., 2013). Sensitization for sickness behaviors 
may thus entail dual involvement of immunological and psychological factors. 
Such synergism might be applicable to humans as a possible explanatory mechanism for the 
experience of somatic symptoms or syndromes that cannot be fully explained by a present 
medical condition (i.e., functional somatic (FS) syndromes), such as in irritable bowel syndrome, 
fibromyalgia, and chronic fatigue syndrome (Dantzer, 2005). An interesting feature of such a 
dual-factor or interactive model is that it could link two independent observations: First, that FS 
symptoms are associated with a history of elevated stress exposures (Anderberg et al., 2000; 
Heim et al., 2006) and second, that FS symptom onset appears linked with immune activation or 
an increased infection load (Lacourt et al., 2013; Moss-Morris and Spence, 2006).  
The aim of the current study was to investigate the possible synergistic effects of 
psychological stress(-vulnerability) factors and immunological activation on pain sensitivity. 
Increased pain sensitivity (i.e., a lower threshold for describing a stimulus as painful and a 
reduction in the level of pain that is considered tolerable) is a prominent symptom in many FS 
syndromes (Bradley, 2008; Stabell et al., 2013) and a typical aspect of sickness behavior with a 
reasonable degree of objectivity in humans (c.f., Benson et al., 2012). We assessed perceived 
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stress, cumulative life events, and negative affectivity (NA) as psychological vulnerability 
factors in healthy subjects, followed by a (placebo-controlled) Salmonella typhi vaccine. 
Specifically, we tested the hypothesis that psychological vulnerability factors and immune 
activation by vaccination jointly enhance pain sensitivity. The present study was limited to 
women as they show a substantially higher prevalence of FS symptoms (Fink et al., 2007).  
 
2. Methods 
2.1 Participants 
The present study involved 27 healthy non-smoking female participants, recruited among 
students and staff of the University of Birmingham by poster advertisement and word of mouth. 
Inclusion criteria were an age between 18 and 50 years old and use of oral contraception. 
Excluded were volunteers reporting diabetes mellitus, asthma, congestive heart failure, any 
psychiatric disorder, recent history of cancer, inflammatory disease, cardiovascular disease, 
chronic obstructive pulmonary disorder, wearing a pacemaker, and those taking any medications 
with known immune modulatory properties. Finally, participants were excluded if they were 
unwell on the day of testing or fell ill between the two test-days. Eligible persons received either 
a monetary incentive or credits for participation. The study protocol was approved by the Health 
Research Authority NRES Committee West Midlands – South Birmingham and all participants 
provided informed consent. 
 
2.2 Study design 
Salmonella typhi capsular polysaccharide vaccine (0.025 mg in 0.5 ml, Typhim Vi, Sanofi 
Pasteur, UK) was used as the immunological challenge. In a placebo-controlled cross-over 
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design, participants were tested in two conditions (i.e. vaccination or saline) on two test-days, 
separated by at least seven days. The order of conditions was counterbalanced across the 
participants and participants were blinded to the conditions. 
 
2.3 Protocol 
Informed consent was obtained on an initial appointment, which involved screening for inclusion 
and exclusion criteria and administration of questionnaires (see below). To reduce variance in 
anti-conceptive hormones within and across participants, participants with monophasic pills were 
tested during the three weeks of pill use, and participants with either biphasic or triphasic pills 
were tested within the first ten days after a stop week. 
With the exception of the injection (vaccine or saline), both test-day protocols were identical. 
Participants reported between 8.00 and 11.00 a.m. at the Behavioral Immunology Laboratory of 
University of Birmingham, upon which baseline measures were obtained of heart rate, blood 
pressure, body temperature, and pain sensitivity. A blood sample was obtained approximately 15 
minutes after arrival. Next, the participants performed several cognitive tasks (data not reported 
here), and were subsequently injected with either vaccine or saline followed by a 30 minute rest. 
All procedures were repeated at six hours post-injection, which coincides with a peak increase in 
vaccine-induced IL-6 and leucocytosis (Paine et al., 2013). Participants were allowed to leave the 
laboratory in between test-sessions.  
 
2.4 Immunological measures 
Blood samples were obtained by venipuncture and collected in vacutainers (Becton & 
Dickenson), and EDTA plasma and serum was subsequently extracted. Analyses for white blood 
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cell (WBC) count and differential were done using a Coulter counter (Beckman Coulter, Inc.). 
Serum was analysed for the inflammatory markers interleukin-6 (IL-6) and tumor necrosis 
factor-alpha (TNF-α) using high sensitivity ELISAs (Quantikine HS Human IL-6 ELISA and 
Quantikine HS Human TNF-α, both R&D Systems, UK) in accordance with the manufacturer’s 
instructions. The reported sensitivity of the assays was 0.039 pg/ml and 0.106 pg/ml for IL-6 and 
TNF- α respectively, with recorded intra-assay and inter-assay variations both <10%. 
 
2.5 Stress sensitivity and psychological stress 
As a measure of stress sensitivity, negative affectivity (NA) was measured with the NA subscale 
of the Positive and Negative Affect Scale (PANAS) (Watson et al., 1988). Psychological stress 
was measured with the Perceived Stress Questionnaire (PSQ) (Levenstein et al., 1993) and the 
Life Events Scale for Students (LESS) (Clements and Turpin, 1996; Linden, 1984). A detailed 
description of all scales is provided in the online supplement. 
 
2.6 Pain sensitivity 
Pressure pain threshold and pressure pain tolerance were assessed using a digital pressure 
algometer (FPX50; Wagner Pain Test
TM
, Greenwich, USA). The procedure for assessing 
pressure pain sensitivity has been described elsewhere (Lacourt et al., 2012). Briefly, a pressure 
was applied and gradually increased at a rate of 100 kPa/s until the participant indicated the force 
to become unpleasant (for pain threshold) or unbearable (for pain tolerance), upon which the 
pressure was released. Pain thresholds were assessed three times at four body points to obtain a 
general body measure: bilaterally at the calf muscle belly and on the lower back at the paraspinal 
muscles of L3. A mean pain threshold was calculated by averaging over the last two 
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measurements of all body points. Pressure pain tolerance was measured on the thumbnail of the 
non-dominant hand. Although a general body measure taken at multiple anatomical sites would 
have been preferable for this measure too, multiple measures of pain tolerance were considered 
too burdensome for the participants. Pain tolerance measurements were repeated (with a 
minimum of 30 s in between measurements) until the participant indicated that the pain tolerance 
level was reached. The highest obtained pressure was used as pain tolerance in the analyses. 
These algometric pain sensitivity measures showed good test-retest reliability for tests 
repeated within one session (intraclass correlation coefficient (ICC) > .80) (Lacourt et al., 2012; 
Potter et al., 2006) and over days (ICC > .70) (Potter et al., 2006). 
 
2.7 Statistical analyses 
The questionnaires did not have any missing data (with the exception of the LESS item “parent 
losing job”, N=6) and normality was adequate for all scales without visual outliers. IL-6 and 
TNF-α plasma concentrations were log-transformed to gain a normal distribution, after which no 
visual outliers were detected. Pain threshold measures showed moderate skewness and were 
square root transformed. Transformed and non-transformed pain data yielded similar results and 
the latter were reported. 
The effects of vaccination were analysed with 2 Condition (saline, vaccination) x 2 Time (pre-
injection, post-injection) repeated measures analyses of variance (ANOVAs). The effects of NA 
and stress were analysed by separately adding these factors as covariates to the models 
(ANCOVAs). In case of a significant three-way interaction (Condition x Time x Stress), 
difference-scores were calculated for pain sensitivity and threshold (Δ = post-injection scores 
minus pre-injection scores), resulting in Δ-saline and Δ-vaccine change-scores. Separate 
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regression analyses were then performed with the Δ-variables as dependent variable and the 
psychological factor of interest as predictor. Bonferroni correction was used to account for 
multiple testing, resulting in an alpha of .016 for the ANCOVAs and .025 for the regression 
analyses. The manufacturer delivered vaccines from two lots, therefore, batch was included as 
additional factor in all analyses. Data were analysed using SPSS for windows 20.1 (IBM SPSS 
Inc, Chicago). 
 
3. Results 
3.1 Sample characteristics 
Two participants were excluded from the analyses because of illness between test-days. Mean 
age of the final sample (N = 25) was 22.28 years (SD: 3.39, range: 18 – 30). Mean BMI was 
22.90 (SD: 2.76, range: 18.93 – 29.74), six participants were overweight with a BMI > 25. Mean 
scores (SD, range) for NA were 19.40 (5.92, 10 – 33), for Perceived Stress 71.80 (12.93, 52 – 
94), and for Life Events 283.56 (125.62, 73 – 495).  
 
3.2 Main effects of vaccination 
Descriptives for the pain and immune outcomes are provided in Table 1. With the alpha set at 
.016 vaccination was found to significantly increase WBC (+100%; condition x time: F (1,23) = 
42.19, p < .001) and IL-6 (+670%; condition x time: F (1,23) = 33.37, p < .001). No effect of 
vaccination was found for TNF-α (condition x time: F (1,23) = 0.14, p = .71). Batch did not 
show an interaction with condition x time in any of the analyses.  
Vaccination did not exhibit an effect on pain threshold (condition x time F (1,23) = 0.24, p = 
.63) or pain tolerance (condition x time: F (1,23) = 1.23, p = .28). Post-hoc analyses showed a 
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main effect for condition order, indicating an association between vaccination and pain tolerance 
in those receiving the vaccine first (online supplement, Table S1). 
 
3.3 Vaccine-by-stress interaction effects 
A significant 3-way interaction was found for NA with pain tolerance as dependent variable 
(condition x time x NA: F (1,22) = 9.45, p = .006). Subsequent regression analyses (alpha set at 
.025) showed that NA was related to a decrease in pain tolerance (i.e., a negative Δ-score) in the 
vaccine condition (β = -.57, t (22) = -2.96, p = .007) but not in the saline condition (β = .25, t 
(22) = 1.16, p = .26) (see Figure 1). Post-hoc analyses provided some indication that this relation 
between NA and vaccination on Δ-pain tolerance was apparent for participants that received 
vaccination on their first test-day (rspearman = -.76, p = .01) and not for participants that received 
vaccination on their second test-day (rspearman  = .13, p = .64). No significant interactions were 
found for NA with pain threshold as dependent variable or for the Perceived stress and Life 
Event measures. 
 
4. Discussion 
The current study set out to test the hypothesis that inflammatory mechanisms and stress or 
stress-vulnerability may interactively determine pain sensitivity. In support of this idea, the 
results showed that higher levels of NA were associated with lower tolerance to pain during 
vaccine-induced low-grade inflammation. To our knowledge, our results are the first 
experimental evidence from human studies that NA and inflammatory factors can interact to 
induce increased expression of pain symptoms, reflecting that NA may induce sensitivity for this 
aspect of sickness behaviour in humans. NA is one of the psychological factors most robustly 
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linked to physical symptom reporting and an established vulnerability factor for the experience 
of FS symptoms (Smolderen et al., 2007; Van Diest et al., 2005; Watson & Pennebaker, 1989). 
While both high NA and immunological triggers are associated with the development of 
functional somatic symptoms (e.g., De Gucht, 2002; Lacourt et al., 2013), neither of these factors 
alone seems to have sufficient predictive value. The interaction between NA and inflammation 
reported here is proposed as an explanation for this observation, proposing that both factors 
might be required. The here reported interaction between NA and inflammation is proposed as an 
explanation for this observation by implying that both factors are needed.  
NA, but not perceived stress or life events interacted with inflammation to increase pain 
sensitivity. NA reflects proneness to subjective distress and unpleasurable engagement (Watson 
et al., 1988), and is highly correlated with the personality trait neuroticism (Wilson and Gullone, 
1999). Perceived stress and life events on the other hand represent the experience of stress. 
Possibly, it is the more general negative state as opposed to specific events or experiences that 
primes the system for inflammatory effects on pain sensitivity. 
The effects of systemic inflammation on pain sensitivity and the moderating effect of 
psychological stressors have been well described in animal models (Anisman et al., 2007; Gibb 
et al., 2013). These models identified as key mechanism the activation of glia cells by 
inflammatory mediators, which in turn alter neuronal functioning along the pain pathway (Hains 
et al., 2010; Watkins et al., 2007). Recently a mechanism was proposed by Frank et al. (2013) to 
explain how stress acts on central immune regulation, based on data showing that stress-related 
increases of glucocorticoids (which typically have an anti-inflammatory effect) can also enhance 
inflammatory responses to stressors, probably by sensitization of glia cells (Frank et al., 2013).  
Accordingly, high NA individuals might (as a result of frequent perceived stress) have primed 
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microglia cells for new challenges. These findings from experimental animal studies provide 
material for further mechanistic studies in humans. 
NA predicted vaccine-induced changes in pain tolerance but not pain threshold. Although 
pain threshold and pain tolerance are both considered measures of pain sensitivity, there is 
evidence that they represent different processes: An earlier study using the same pain assessment 
methodology showed that pain tolerance is only modestly correlated to pain threshold (r≈.40) but 
moderately related to subjective sensory and affective pain ratings (r≈.60) (Lacourt et al., 2012). 
Pain threshold on the other hand showed low correlations with pain ratings (r≈.30). Thus, pain 
tolerance seems to incorporate an affective aspect of pain sensitivity, while pain threshold seems 
to represent a more objective sensory aspect. The present data is suggestive of the idea that the 
interaction between NA and inflammation is related to emotional aspects of pain sensitivity. It 
has been proposed that sickness behaviour is a motivational state “that reorganizes perception 
and action” (Dantzer, 2001). In this view, the affective or emotional aspects of pain sensitivity 
would be expected to change during inflammation, as these aspects underlie the individual’s 
withdrawing behaviour that facilitate recuperation from infection. This affective aspect in pain 
sensitivity is also seen in FS syndrome patients, where relations between psychological distress 
and pain sensitivity measures are commonly reported (Bradley, 2008; Verne et al., 2001). 
 
4.1 Limitations and recommendations 
A number of limitations should be noted. First, state negative affect was not assessed in this 
study and it cannot be ruled out that the observed decrease in pain tolerance was a consequence 
of increases in negative mood state induced by low-grade inflammation. The possibility of such 
an effect of mood is tentatively suggested by the observation that the effect of NA and 
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vaccination on pain tolerance might depend on the order  in which vaccination was administered 
(i.e., receiving the vaccine first), which might reflect a result of anticipatory anxiety. An effect of 
state-anxiety  has recently been observed in an elegant study using the (more potent) endotoxin 
paradigm (Wegner et al., 2014). Thus, the notion of an effect of state mood deserves further 
exploration in future studies. Second, the sample used in this study was relatively small, leading 
to low power to detect smaller effects. Replication in better powered studies is needed to 
determine if the observed interactive effect for NA generalizes to other psychological 
vulnerability factors. Third, only healthy female participants were included which reduces 
generalizability of our results. Since gender differences have been reported for pain sensitivity 
(Fillingim et al., 2009), it is possible that such differences may also exist in inflammation-
induced changes in pain sensitivity. Finally, two different batches of the Salmonella typhi 
vaccine were used, thereby possibly enhancing between-participants variance in immunological 
activity. However, batch was included as a factor in all analyses, and no batch effects could be 
demonstrated. 
 
In summary, NA, a trait related to a negative or stressful interpretation of events and an 
established vulnerability factor for the development of FS symptoms, was found to interact with 
vaccine-induced low-grade inflammation on pain tolerance. These results are in line with animal 
models on the synergistic effects of inflammation and psychological stress on subsequent 
sickness behaviors and may open new approaches to understanding somatic symptom reporting 
in humans. 
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Table 1. Mean (untransformed) ±SD of the dependent variables per assessment.  
 
Figure 1. Scatterplot depicting the relation between NA and change in pain tolerance (a negative 
score indicates a decrease in pain tolerance from pre- to post-injection) within the saline 
condition (left panel) and the vaccine condition (right panel). 
 
 
  
 Saline  Vaccination 
 Pre-injection Post-injection  Pre-injection Post-injection 
WBC (10
9
/L) 5.82 ±1.78 7.21 ±1.96*  5.80 ±1.33 10.57 ±3.37* 
Interleukin-6 (pg/ml) 1.77 ±2.86 1.69 ±2.34  0.84 ±1.25 5.66 ±3.33* 
TNF-α (pg/ml) 2.00 ±3.37 5.37 ±9.35  3.89 ±6.17 6.45 ±9.99 
      
Pain threshold (kPa) 391.27 ±186.55 405.02 ±175.53  398.15 ±150.26 392.27 ±148.79 
Pain tolerance (kPa) 930.65 ±189.97 907.12 ±204.79  954.19 ±168.39 899.27 ±213.63 
* Significantly different from Pre-injection at p<.001. 
 
  
  
Stress sensitivity and immune activation interacted to increase sensitivity to pain. 
Trait negative affect predicted lower pain tolerance under induced mild inflammation.  
This interaction suggests a mechanism that may underlie functional pain symptoms. 
 
 
 
